🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Diagnostic Value of Photon-Counting CT in Subsegmental Pulmonary Embolism

Recruitingn/aAges 18 Years - anyAllSecond Affiliated Hospital, Zhejiang University, …
NCT07575503 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Pulmonary embolism (PE) is a serious and potentially life-threatening condition caused by blood clots in the lungs. A particular type, subsegmental pulmonary embolism (SSPE), involves very small branches of the pulmonary arteries. Although these clots occur in smaller vessels, their risk of recurrence and complications may be similar to larger clots. Conventional CT pulmonary angiography (CTPA) is the standard imaging test for suspected PE, but image quality can sometimes be limited by motion artifacts, poor contrast filling, or body habitus, making the detection of SSPE challenging. Photon-counting computed tomography (PCCT) is a new CT technology that provides higher image resolution, lower radiation dose, and improved visualization of small blood vessels. Early studies suggest PCCT may reduce motion artifacts and increase the accuracy of detecting SSPE compared with conventional CT.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 18 years 2. Clinical manifestations supporting the diagnosis of acute pulmonary embolism, including: Acute onset or progressive dyspnea Unexplained hypoxemia Chest pain Hemoptysis Syncope or presyncope Combined with abnormal findings on electrocardiogram, echocardiography, or pulse oximetry 3. Revised simplified Geneva score ≥ 3 4. Written informed consent obtained from the patient or the patient's legally authorized representative Exclusion Criteria: 1. Patients requiring prophylactic or therapeutic doses of anticoagulant medication for reasons other than venous thromboembolism (VTE). 2. Life expectancy less than three months. 3. Patients unable to undergo CT scanning due to severe condition or hemodynamic instability. 4. History of allergy to contrast media, renal insufficiency (creatinine clearance \< 30 mL/min), or ongoing long-term dialysis. 5. Pregnancy. 6. Refusal to provide informed consent or inability to complete follow-up for any reason.
💊

What it tests

  • Not listed
📍

Where

1 site
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy